Jubilant Life Sciences Announces Launch of ‘JUBI-R’ for Treatment of COVID-19

India : Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company has announce that its subsidiary, Jubilant Generics Limited, has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of INR4,700 per vial of 100 mg (lyophilized injection). The Company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network. Jubilant’s 24 hour help line will enhance access to ‘JUBI-R’ during these pandemic times, where timely access to the drug may prove critical to treatment outcomes.

In order to increase accessibility of ‘JUBI-R’ to patients below the poverty line and to front line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programs in India aimed at distribution of the drug.

Mr. Hari S. Bhartia, Co-Chairman, Jubilant Pharma Limited stated “ The Company’s ability to launch this product in such short timelines highlights our R&D and manufacturing capabilities and our continued commitment to provide leading healthcare solutions. Through the Jubilant Bhartia Foundation, we will distribute the drug on compassionate basis to save precious lives of people through unique programs.”